Looking to build in red-hot viral vector space, Thermo Fisher inks $878M deal for Belgian manufacturer's 2 plants
Between Covid-19 vaccines and gene therapies, the contract manufacturing market for viral vector tech has grown at a rapid clip. Thermo Fisher Scientific, already one …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.